DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing and dispensing bortezomib, melphalan, and prednisone. A. Bortezomib 1. Use bortezomib powder for injection. 2. Reconstitute with 0.9% sodium chloride (NS). 3. The manufacturer recommends using different concentrations for intravenous (IV) and subcutaneous (SQ) injection 15 : a. IV: Final concentration -1 mg/mL. b. SQ: 2.5 mg/mL 4. Some institutions prepare all doses at a concentration of 2.5 mg/mL for either IV or SQ injection. 
DRUG ADMINISTRATION
A. Bortezomib 1. Boretzomib is given by rapid (3-5 seconds) IV or SQ injection. 2. Most of the studies reviewed did not specify the route of bortezomib administration, although some did mention following the regimen used in the VISA trial, which gave bortezomib IV. 2, 3, 5, 7, [9] [10] [11] [12] 3. Several studies reviewed specified that the bortezomib was given IV. 4, 6, 8, 13 4. In one study, the bortezomib was given SQ. 14 5. Subcutaneous administration of bortezomib has been reported to significantly decrease the incidence of neurotoxicity. Patients who do experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is not recommended. [16] [17] [18] [19] [20] C. Hematopoietic Growth Factors: Accepted practice guidelines and pharmacoeconomic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended.
22,23
Febrile neutropenia was not reported in the trials reviewed. Severe (grade 3 or 4) neutropenia was reported in 10% to 77% of patients. [2] [3] [4] [5] [6] [7] [8] Prophylactic use of CSFs is not recommended. 22, 23 CSFs may be appropriate in some patients and should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of VMP.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:/ctep. info.nih.gov). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. 
